Role of plasminogen/plasmin system components and matrix metalloproteases in retinal artery occlusion following cardiac surgery
DOI:
https://doi.org/10.31288/oftalmolzh202463339Keywords:
retina, retinal artery occlusion, valvular heart disease, cardiosurgical interventions, plasminogen/plasmin system, MMP-9Abstract
Purpose: To assess the impact of plasminogen/plasmin system components and matrix metalloproteases (MMPs) on the development of retinal artery occlusion (RAO) after cardiac surgery for valvular heart disease (VHD).
Material and Methods: Seventy three patients who underwent cardiac surgery for VHD were included in the study. Of these, 23 patients older than 60 years who had conventional-access mechanical prosthetic valve replacement with cardiopulmonary bypass were stratified into the group of high risk (HR) for RAO. Ten HR patients developed branch or central RAO. The low-risk (LR) group comprised 50 patients younger than 60 years who had valvuloplasty via a minimally invasive approach or the femoral artery using a biological implant. The control group comprised 15 patients who had no cardiac disease. Coagulogram indices and D-dimer were measured. Enzyme-linked immunosorbent assay kits were used to determine plasma plasminogen activator inhibitor (PAI)-1, plasmin-α2-antiplasmin complex (PAP), and tissue inhibitor of MMP-3 (TIMP-3) levels. MMP levels were determined by enzyme gelatin zymography.
Results: The PAI-1 levels were three times higher in HR groups than in controls. Mean PAI-1 levels were almost identical in patients who developed RAO and patients who did not develop RAO. The level of PAP in HR patients was 4-6 times lower than in the control group. MMP-9 activity was 2.5-fold lower in HR group patients who did not develop RAO than in those who developed RAO. In the latter patients, the level of plasma TIMP-3 was 2.3-fold lower than in controls. Mean plasma TIMP-3 level was almost identical in patients who did not develop RAO and LR patients. The mean plasma D-dimer level was the highest in patients who developed RAO; this was 16-fold higher than in the control group, and 11-fold higher than in patients who did not develop RAO.
Conclusion: High functional activity of plasmin and proteolytic MMP-9 activity are the major factors of the fibrinolytic system which cause the development of RAO in patients undergoing cardiac surgery. Regulators of plasminogen/plasmin activation (such as PAI-1 and PAP) and TIMP-3 do not play a substantial role in the development of complications in the form of RAO.
References
Aluru JS, Barsouk A, Saginala K, Rawla P, Barsouk A. Valvular Heart Disease Epidemiology. Med Sci (Basel). 2022 Jun 15;10(2):32. https://doi.org/10.3390/medsci10020032
Maganti K, Rigolin VH, Sarano ME, Bonow EO. Valvular Heart Disease: Diag-nosis and Management. Mayo Clin Proc. 2010 May;85(5):483-500. https://doi.org/10.4065/mcp.2009.0706
Rubin DS, Matsumoto MM, Moss HE, Joslin CE, Tung A, Roth S. Ischemic Optic Neuropathy in Cardiac Surgery: Incidence and Risk Factors in the United States from the National Inpatient Sample 1998 to 2013. Anesthesiology. 2017 May;126(5):810-821. https://doi.org/10.1097/ALN.0000000000001533
Panchenko YuO, Kovalchuk NYa. [Risk factors for the development of retinal artery occlusions after cardiac surgery for valvular heart disease]. Clinical Ophthalmology. 2023;11(3):31-5. Ukrainian. https://doi.org/10.22141/2309-8147.11.3.2023.340
Lijnen RH, Van B H, Lupu F, Moons L, Carmeliet P, and Collen D. Function of the Plasminogen/Plasmin and Matrix Metalloproteinase Systems After Vascular Injury in Mice With Targeted Inactivation of Fibrinolytic System Genes. Arterioscler Thromb Vasc Biol. 1998;18(7): 1035-45. https://doi.org/10.1161/01.ATV.18.7.1035
Leebeek FW, Kluft C, Knot EA, et al. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin. J Am Coll Cardiol. 1990;15(6):1212-20. https://doi.org/10.1016/S0735-1097(10)80003-8
Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1. PLoS ONE. 2011;6(11):e26762. https://doi.org/10.1371/journal.pone.0026762
Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010 Oct;28(5):e72-91. https://doi.org/10.1111/j.1755-5922.2010.00171.x
Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes. 1997; 46: 860-7. https://doi.org/10.2337/diab.46.5.860
Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci. 2007; 12: 2957-66. https://doi.org/10.2741/2285
Snoek-van Beurden PA, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques. 2005 Jan;38(1):73-83. https://doi.org/10.2144/05381RV01
Sillen M, Declerck PJ. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target? Int J Mol Sci. 2021 Mar 8;22(5):2721. https://doi.org/10.3390/ijms22052721
Weisberg AD, Albornoz F, Griffin JP, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25: 365-71. https://doi.org/10.1161/01.ATV.0000152356.85791.52
Reed GL, Houng AK, Singh S, Wang D. α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke. Semin Thromb Hemost. 2017 Mar;43(2):191-9. https://doi.org/10.1055/s-0036-1585077
Ho CH, Wang SP. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction. Thromb Res. 1990 May 1;58(3):331-41. https://doi.org/10.1016/0049-3848(90)90102-I
Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17. https://doi.org/10.1161/hq0701.093685
Singh S, Houng AK, Wang D, Reed GL. Physiologic variations in blood plasminogen levels affect outcomes after acute cerebral thromboembolism in mice: a pathophysiologic role for microvascular thrombosis. J Thromb Haemost. 2016 Sep;14(9):1822-32. https://doi.org/10.1111/jth.13390
Rosell A, Cuadrado E, Ortega-Aznar A, et al. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39(4):1121-6. https://doi.org/10.1161/STROKEAHA.107.500868
Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol. 2008;8(1):82-9. https://doi.org/10.1016/j.coph.2007.12.001
Cooper JA, Lo SK, Malik AB. Fibrin is a determinant of neutrophil sequestration in the lung. Circ Res. 1988;63(4):735-741. https://doi.org/10.1161/01.RES.63.4.735
Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol. 2001;21(12):2093-8. https://doi.org/10.1161/hq1201.100255
Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12(4):441-5. https://doi.org/10.1038/nm1387
Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke. 2002;33(11):2711-7. https://doi.org/10.1161/01.STR.0000033932.34467.97
Lafleur MA, Forsyth PA, Atkinson SJ, Murphy G, Edwards DR. Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. Biochem Biophys Res Commun. 2001;282:463-73. https://doi.org/10.1006/bbrc.2001.4596
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Natrus L. V., Kovalchuk N. Ia., Tanasiichuk I. S., Panchenko Iu. O.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.